Payment overview · 2025
General Payments
$1,583.07
68 reported records · 19 companies
Healthcare provider profile · identity verified
Joseph L Pratt, MD
Allopathic & Osteopathic Physicians|Family Medicine · CORINTH, MS · NPI 1417953233
Verified facts
What the public records show
CMS Open Payments records show Joseph L Pratt, MD received $1,583.07 in general payments during 2025 across 68 reported records.
Alpha Cognition USA, Inc. accounted for 28.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Gemtesa, Kerendia, Linzess, Mounjaro, Nurtec Odt, Rexulti, Trelegy Ellipta, Vraylar, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rinvoq by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 206 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 228 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 575 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trulance by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Xifaxan by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Alpha Cognition USA, Inc. | Unresolved — no canonical attribution shown | $443.04 | 28.0% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $320.53 | 20.2% | 23 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $167.14 | 10.6% | 7 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $158.31 | 10.0% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $78.77 | 5.0% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $67.97 | 4.3% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $41.79 | 2.6% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $40.25 | 2.5% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $40.19 | 2.5% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $34.62 | 2.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.57 | 2.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $30.25 | 1.9% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $23.42 | 1.5% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $21.85 | 1.4% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $19.62 | 1.2% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $16.26 | 1.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.20 | 1.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.75 | 1.0% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $14.54 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,567.08 | 67 |
| Education | $15.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Zunveyl Normalized: zunveyl |
Drug | Alpha Cognition USA, Inc. | $443.04 | 4 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $158.31 | 6 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $134.23 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $124.77 | 4 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $108.90 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $108.16 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $92.11 | 2 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $89.02 | 4 | 2025 |
Source payment records
|
|||||
| EMBLAVEO Normalized: emblaveo |
Drug | ABBVIE INC. | $72.32 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $65.49 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $61.69 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $54.82 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $45.16 | 6 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $41.79 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $40.82 | 6 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $40.25 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $36.54 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $34.62 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.57 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $32.57 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $30.25 | 2 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $28.95 | 2 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $23.42 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $21.85 | 1 | 2025 |
Source payment records
|
|||||
| ENROUTE Transcarotid Stent Normalized: enroute transcarotid stent |
Device | Boston Scientific Corporation | $19.62 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.75 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $14.54 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 575 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 171 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 141 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 119 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 121 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 79 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
141 | 27 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
80 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
94 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
171 | 32 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
49 | 49 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
69 | 60 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
121 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
206 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
119 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
90 | 15 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
228 | 45 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
575 | 73 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
21 | 21 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
79 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 1489 | 277 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1439 | 301 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1273 | 257 |
| Potassium Chloride | Potassium Chloride | 1266 | 250 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1078 | 237 |
| Alprazolam | Alprazolam | 976 | 160 |
| Omeprazole | Omeprazole | 862 | 204 |
| Amlodipine Besylate | Amlodipine Besylate | 841 | 191 |
| Furosemide | Furosemide | 808 | 199 |
| Metoprolol Succinate | Metoprolol Succinate | 790 | 165 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 760 | 189 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 731 | 170 |
| Famotidine | Famotidine | 644 | 146 |
| Buspirone Hcl | Buspirone Hcl | 633 | 92 |
| Clopidogrel | Clopidogrel Bisulfate | 631 | 140 |
| Montelukast Sodium | Montelukast Sodium | 599 | 139 |
| Trazodone Hcl | Trazodone Hcl | 597 | 118 |
| Tamsulosin Hcl | Tamsulosin Hcl | 592 | 136 |
| Metformin Hcl | Metformin Hcl | 581 | 121 |
| Tizanidine Hcl | Tizanidine Hcl | 577 | 125 |
| Eliquis | Apixaban | 575 | 73 |
| Losartan Potassium | Losartan Potassium | 565 | 128 |
| Lisinopril | Lisinopril | 558 | 119 |
| Escitalopram Oxalate | Escitalopram Oxalate | 540 | 110 |
| Duloxetine Hcl | Duloxetine Hcl | 480 | 92 |
| Pregabalin | Pregabalin | 467 | 90 |
| Lorazepam | Lorazepam | 463 | 77 |
| Tramadol Hcl | Tramadol Hcl | 423 | 103 |
| Carvedilol | Carvedilol | 400 | 78 |
| Temazepam | Temazepam | 373 | 76 |
| Ezetimibe | Ezetimibe | 359 | 102 |
| Zolpidem Tartrate | Zolpidem Tartrate | 349 | 51 |
| Clonazepam | Clonazepam | 347 | 55 |
| Ondansetron Odt | Ondansetron | 347 | 137 |
| Meloxicam | Meloxicam | 344 | 109 |
| Sertraline Hcl | Sertraline Hcl | 343 | 63 |
| Simvastatin | Simvastatin | 340 | 74 |
| Hydrochlorothiazide | Hydrochlorothiazide | 336 | 89 |
| Doxycycline Hyclate | Doxycycline Hyclate | 319 | 163 |
| Quetiapine Fumarate | Quetiapine Fumarate | 307 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 304 | 58 |
| Xarelto | Rivaroxaban | 289 | 27 |
| Donepezil Hcl | Donepezil Hcl | 287 | 60 |
| Diazepam | Diazepam | 284 | 53 |
| Mirtazapine | Mirtazapine | 283 | 56 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 280 | 52 |
| Diclofenac Sodium | Diclofenac Sodium | 273 | 66 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 268 | 58 |
| Citalopram Hbr | Citalopram Hydrobromide | 264 | 50 |
| Celecoxib | Celecoxib | 256 | 67 |
| Allopurinol | Allopurinol | 247 | 62 |
| Sucralfate | Sucralfate | 241 | 54 |
| Ozempic | Semaglutide | 228 | 45 |
| Ibuprofen | Ibuprofen | 225 | 64 |
| Ropinirole Hcl | Ropinirole Hcl | 221 | 35 |
| Methylprednisolone | Methylprednisolone | 219 | 142 |
| Bumetanide | Bumetanide | 213 | 40 |
| Prednisone | Prednisone | 213 | 85 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 209 | 63 |
| Fluconazole | Fluconazole | 208 | 102 |
| Clonidine Hcl | Clonidine Hcl | 207 | 58 |
| Jardiance | Empagliflozin | 206 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 205 | 42 |
| Fluoxetine Hcl | Fluoxetine Hcl | 200 | 35 |
| Promethazine Hcl | Promethazine Hcl | 197 | 62 |
| Spironolactone | Spironolactone | 196 | 52 |
| Doxazosin Mesylate | Doxazosin Mesylate | 193 | 40 |
| Levetiracetam | Levetiracetam | 190 | 31 |
| Meclizine Hcl | Meclizine Hcl | 188 | 68 |
| Hydralazine Hcl | Hydralazine Hcl | 183 | 45 |
| Levofloxacin | Levofloxacin | 182 | 124 |
| Memantine Hcl | Memantine Hcl | 182 | 30 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 179 | 31 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 175 | 43 |
| Paroxetine Hcl | Paroxetine Hcl | 172 | 24 |
| Farxiga | Dapagliflozin Propanediol | 171 | 32 |
| Metformin Hcl Er | Metformin Hcl | 171 | 37 |
| Sotalol | Sotalol Hcl | 168 | 42 |
| Azithromycin | Azithromycin | 167 | 99 |
| Estradiol | Estradiol | 166 | 40 |
| Amiodarone Hcl | Amiodarone Hcl | 165 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 165 | 59 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 162 | 41 |
| Ondansetron Hcl | Ondansetron Hcl | 159 | 52 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 150 | 94 |
| Cefdinir | Cefdinir | 148 | 104 |
| Dicyclomine Hcl | Dicyclomine Hcl | 147 | 39 |
| Torsemide | Torsemide | 145 | 31 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 143 | 44 |
| Topiramate | Topiramate | 143 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 142 | 37 |
| Linzess | Linaclotide | 141 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 141 | 28 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 140 | 42 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 138 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 135 | 97 |
| Propranolol Hcl | Propranolol Hcl | 135 | 32 |
| Raloxifene Hcl | Raloxifene Hcl | 133 | 26 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 132 | 53 |
| Alendronate Sodium | Alendronate Sodium | 131 | 46 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 131 | 25 |
| Methocarbamol | Methocarbamol | 129 | 45 |
| Amitriptyline Hcl | Amitriptyline Hcl | 127 | 25 |
| Aripiprazole | Aripiprazole | 126 | 28 |
| Nifedipine Er | Nifedipine | 126 | 36 |
| Glimepiride | Glimepiride | 121 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 121 | 26 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 121 | 33 |
| Mounjaro | Tirzepatide | 119 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 118 | 34 |
| Divalproex Sodium | Divalproex Sodium | 114 | 12 |
| Atenolol | Atenolol | 109 | 27 |
| Metoclopramide Hcl | Metoclopramide Hcl | 107 | 29 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 105 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 101 | 18 |
| Januvia | Sitagliptin Phosphate | 100 | 11 |
| Baclofen | Baclofen | 98 | 20 |
| Risperidone | Risperidone | 96 | 17 |
| Fenofibrate | Fenofibrate | 94 | 22 |
| Myrbetriq | Mirabegron | 94 | 17 |
| Olanzapine | Olanzapine | 93 | 17 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 92 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 92 | 22 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 91 | 35 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 90 | 22 |
| Trulicity | Dulaglutide | 90 | 15 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 89 | 12 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 87 | 20 |
| Bethanechol Chloride | Bethanechol Chloride | 85 | 11 |
| Megestrol Acetate | Megestrol Acetate | 83 | 29 |
| Nystatin | Nystatin | 81 | 51 |
| Oxybutynin Chloride | Oxybutynin Chloride | 81 | 11 |
| Synthroid | Levothyroxine Sodium | 80 | 16 |
| Ipratropium Bromide | Ipratropium Bromide | 79 | 29 |
| Pioglitazone Hcl | Pioglitazone Hcl | 79 | 23 |
| Xifaxan | Rifaximin | 79 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 78 | 22 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 78 | 16 |
| Valsartan | Valsartan | 78 | 17 |
| Lamotrigine | Lamotrigine | 77 | 16 |
| Warfarin Sodium | Warfarin Sodium | 77 | 16 |
| Finasteride | Finasteride | 73 | 18 |
| Theophylline Er | Theophylline Anhydrous | 71 | 11 |
| Clindamycin Hcl | Clindamycin Hcl | 70 | 50 |
| Lactulose | Lactulose | 70 | 21 |
| Lovastatin | Lovastatin | 70 | 12 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 69 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 69 | 60 |
| Methenamine Hippurate | Methenamine Hippurate | 68 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 68 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 66 | 43 |
| Midodrine Hcl | Midodrine Hcl | 65 | 11 |
| Terazosin Hcl | Terazosin Hcl | 64 | suppressed |
| Digoxin | Digoxin | 63 | 15 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 61 | 16 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 61 | 14 |
| Amoxicillin | Amoxicillin | 59 | 33 |
| Bupropion Hcl Sr | Bupropion Hcl | 58 | suppressed |
| Mupirocin | Mupirocin | 58 | 40 |
| Dutasteride | Dutasteride | 57 | 16 |
| Metolazone | Metolazone | 57 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 57 | 15 |
| Primidone | Primidone | 57 | 15 |
| Entresto | Sacubitril/Valsartan | 56 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 56 | 12 |
| Clobetasol Propionate | Clobetasol Propionate | 55 | 39 |
| Hydrocortisone | Hydrocortisone | 54 | 16 |
| Brilinta | Ticagrelor | 51 | suppressed |
| Chlorthalidone | Chlorthalidone | 51 | 16 |
| Atrovent Hfa | Ipratropium Bromide | 50 | suppressed |
| Febuxostat | Febuxostat | 50 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 50 | 20 |
| Modafinil | Modafinil | 50 | suppressed |
| Naproxen | Naproxen | 50 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 50 | 37 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 49 | 15 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 49 | 49 |
| Latanoprost | Latanoprost | 49 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 49 | 14 |
| Doxepin Hcl | Doxepin Hcl | 48 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 48 | 21 |
| Ranolazine Er | Ranolazine | 48 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 48 | 21 |
| Bupropion Xl | Bupropion Hcl | 47 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 46 | 15 |
| Colestipol Hcl | Colestipol Hcl | 46 | suppressed |
| Desloratadine | Desloratadine | 46 | 25 |
| Lansoprazole | Lansoprazole | 46 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 45 | suppressed |
| Ramelteon | Ramelteon | 45 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 44 | 14 |
| Metronidazole | Metronidazole | 43 | 35 |
| Novolog Flexpen | Insulin Aspart | 43 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 43 | 11 |
| Ceftriaxone | Ceftriaxone Sodium | 42 | 33 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 42 | 25 |
| Flecainide Acetate | Flecainide Acetate | 42 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 42 | 14 |
| Vraylar | Cariprazine Hcl | 42 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 41 | 29 |
| Colchicine | Colchicine | 40 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 40 | 12 |
| Glipizide | Glipizide | 39 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 38 | 20 |
| Benztropine Mesylate | Benztropine Mesylate | 38 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 37 | suppressed |
| Nitroglycerin | Nitroglycerin | 37 | 27 |
| Novolog | Insulin Aspart | 37 | 11 |
| Nurtec Odt | Rimegepant Sulfate | 37 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 36 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 36 | 19 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 25 |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 35 | 24 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 35 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 35 | 24 |
| Gemfibrozil | Gemfibrozil | 34 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 34 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 34 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 33 | suppressed |
| Repatha Sureclick | Evolocumab | 33 | suppressed |
| Trulance | Plecanatide | 33 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 33 | 11 |
| Indomethacin | Indomethacin | 32 | 14 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 32 | 11 |
| Novolin R | Insulin Regular, Human | 31 | suppressed |
| Rexulti | Brexpiprazole | 31 | suppressed |
| Felodipine Er | Felodipine | 30 | 12 |
| Rabeprazole Sodium | Rabeprazole Sodium | 30 | suppressed |
| Dextroamphetamine Sulfate | Dextroamphetamine Sulfate | 29 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 29 | 15 |
| Vascepa | Icosapent Ethyl | 29 | suppressed |
| Cilostazol | Cilostazol | 28 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 28 | suppressed |
| Nateglinide | Nateglinide | 28 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 27 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 27 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 27 | suppressed |
| Clonidine | Clonidine | 26 | suppressed |
| Ertapenem | Ertapenem Sodium | 26 | 17 |
| Ketoconazole | Ketoconazole | 26 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 25 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Insulin Aspart | Insulin Aspart | 25 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 25 | 19 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 25 | 21 |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 24 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Zafirlukast | Zafirlukast | 23 | suppressed |
| Acetazolamide | Acetazolamide | 22 | suppressed |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 22 | 16 |
| Memantine Hcl Er | Memantine Hcl | 22 | suppressed |
| Methimazole | Methimazole | 22 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 22 | suppressed |
| Belsomra | Suvorexant | 21 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 21 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Rizatriptan | Rizatriptan Benzoate | 21 | suppressed |
| Triazolam | Triazolam | 21 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 20 | suppressed |
| Sotalol Af | Sotalol Hcl | 20 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 19 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Ibu | Ibuprofen | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Lacosamide | Lacosamide | 19 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 19 | suppressed |
| Rytary | Carbidopa/Levodopa | 19 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 18 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 18 | 13 |
| Cinacalcet Hcl | Cinacalcet Hcl | 17 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 17 | suppressed |
| Kerendia | Finerenone | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 16 | suppressed |
| Dexilant | Dexlansoprazole | 16 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 16 | suppressed |
| Nadolol | Nadolol | 16 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 16 | suppressed |
| Zaleplon | Zaleplon | 16 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 15 | suppressed |
| Budesonide | Budesonide | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Clarithromycin | Clarithromycin | 15 | 14 |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Insulin Lispro | Insulin Lispro | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Linezolid | Linezolid | 15 | 13 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Praluent Pen | Alirocumab | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Dupixent Pen | Dupilumab | 14 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Imiquimod | Imiquimod | 14 | 12 |
| Nabumetone | Nabumetone | 14 | suppressed |
| Norethindrone | Norethindrone | 14 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 14 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 14 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Permethrin | Permethrin | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | 11 |
| Sps | Sodium Polystyrene Sulfon/Sorb | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Trimethoprim | Trimethoprim | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Zovia 1-35 | Ethynodiol D-Ethinyl Estradiol | 13 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Piroxicam | Piroxicam | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Propylthiouracil | Propylthiouracil | 12 | suppressed |
| Rinvoq | Upadacitinib | 12 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Probenecid | Probenecid | 11 | suppressed |
| Procto-Med Hc | Hydrocortisone | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,583.07 · 68 records | Alpha Cognition USA, Inc. | AIRSUPRA, AVYCAZ, BREZTRI, CREON, DALVANCE, ELIQUIS, EMBLAVEO, ENROUTE Transcarotid Stent, EVENITY, FARXIGA, GEMTESA, Kerendia, Korlym, LINZESS, MOUNJARO, NURTEC ODT, Nayzilam, QULIPTA, REXULTI, SMARTVEST, TEFLARO, TRELEGY ELLIPTA, UBRELVY, VIBERZI, VRAYLAR, Veozah, Wegovy, XIFAXAN, XYOSTED, ZEPBOUND, Zunveyl | 26 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error